<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609827</url>
  </required_header>
  <id_info>
    <org_study_id>P1517152</org_study_id>
    <secondary_id>150811</secondary_id>
    <nct_id>NCT03609827</nct_id>
  </id_info>
  <brief_title>Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients</brief_title>
  <official_title>Population Pharmacokinetics (PK) of Melphalan in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Melphalan is a chemotherapy drug used extensively in bone marrow transplantation. The goal of&#xD;
      this study is to determine what causes some children to have different drug concentrations of&#xD;
      melphalan in their bodies and if drug levels are related to whether or not a child&#xD;
      experiences severe side-effects during their bone marrow transplant. The hypothesis is that&#xD;
      certain clinical and individual factors cause changes in melphalan drug levels in pediatric&#xD;
      bone marrow transplant patients and that high levels may cause severe side-effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melphalan is an alkylating agent with potent antitumor and immunosuppressive properties used&#xD;
      in conditioning regimens of pediatric allogeneic hematopoietic cell transplantation (alloHCT)&#xD;
      to promote stem cell engraftment.&#xD;
&#xD;
      This is a single-center, prospective, non-interventional pharmacokinetics (PK) study&#xD;
      investigating the clinical pharmacology of melphalan in 24 children undergoing allogeneic&#xD;
      hematopoietic stem cell transplant (alloHCT) at University of California, San Francisco&#xD;
      Benioff Children's Hospital.&#xD;
&#xD;
      Patients would receive melphalan regardless of whether or not they decide to consent to PK&#xD;
      sampling.&#xD;
&#xD;
      Melphalan doses will not be adjusted based on PK data.&#xD;
&#xD;
      The investigators will apply the combination of a limited sampling strategy and population PK&#xD;
      methodologies to determine specific factors influencing melphalan exposure in pediatric&#xD;
      alloHCT recipients. Population PK methodologies support the use of sparse sampling and&#xD;
      therefore allow us to investigate drug levels in a pediatric population that would otherwise&#xD;
      not be feasible using traditional intensive PK sampling.&#xD;
&#xD;
      Subjects will undergo PK sampling of plasma melphalan drug concentrations over the duration&#xD;
      of melphalan therapy (3 to 5 days).&#xD;
&#xD;
      To evaluate sources of variability impacting melphalan exposure clinical data will be&#xD;
      obtained from the patient's medical chart on each day of PK sampling.&#xD;
&#xD;
      To assess exposure-response relationships neutrophil engraftment, treatment-related toxicity,&#xD;
      and survival data will be collected through day 100 post-transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Actual">May 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of the Area under the Plasma Concentration versus Time Curve (AUC) of melphalan for HCT in pediatric patients.</measure>
    <time_frame>5min post end of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of the Area under the Plasma Concentration versus Time Curve (AUC) of melphalan for HCT in pediatric patients.</measure>
    <time_frame>15 min post end of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of the Area under the Plasma Concentration versus Time Curve (AUC) of melphalan for HCT in pediatric patients.</measure>
    <time_frame>30 min post end of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of the Area under the Plasma Concentration versus Time Curve (AUC) of melphalan for HCT in pediatric patients.</measure>
    <time_frame>1 hr post end of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of the Area under the Plasma Concentration versus Time Curve (AUC) of melphalan for HCT in pediatric patients.</measure>
    <time_frame>2 hrs post end of infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the event free survival according to the AUC of melphalan</measure>
    <time_frame>1month post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the event free survival according to the AUC of melphalan</measure>
    <time_frame>3 months post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the event free survival according to the AUC of melphalan</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Hematologic Malignancies</condition>
  <condition>Nonmalignant Diseases</condition>
  <condition>Immunodeficiencies</condition>
  <condition>Hemoglobinopathies</condition>
  <condition>Genetic Inborn Errors of Metabolism</condition>
  <condition>Fanconi's Anemia</condition>
  <condition>Thalassemia</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Pediatric patients undergoing Hematopoietic Stem Cell Transplant</arm_group_label>
    <description>Children undergoing allogeneic hematopoietic stem cell transplant (alloHCT) at University of California, San Francisco Benioff Children's Hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>Pediatric patients undergoing Hematopoietic Stem Cell Transplant</arm_group_label>
    <other_name>Evomela</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The target population for the proposed study includes children 0-17 years of age undergoing&#xD;
        alloHCT for the treatment of malignant and nonmalignant disorders. Patients receiving&#xD;
        melphalan over 3 to 5 days are eligible to participate. All patients enrolled in this study&#xD;
        will undergo PK sampling on the inpatient pediatric BMT unit at UCSF Benioff Children's&#xD;
        Hospital. The proposed research will not study any patients receiving melphalan in a clinic&#xD;
        or any other out-patient setting.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children 0-17 years of age&#xD;
&#xD;
          -  Undergoing alloHCT for the treatment of malignant or nonmalignant disorder&#xD;
&#xD;
          -  Receiving melphalan-based preparative regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any child 7-17 years of age unwilling to provide assent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janel R Long-Boyle, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melphalan</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Allogeneic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

